Clinical Trial: Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413250) titled 'Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data' on Feb. 10.

Brief Summary: This is a noninterventional registry-based cohort study utilizing data collected on danicopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry. The primary objectives seek to characterize the long-term safety profile of danicopan as add-on therapy to ravulizumab/eculizumab in participants with PNH.

Study Start Date: Jan. 14

Study Type: OBSERVATIONAL

Condition: Paroxysmal Nocturnal Hem...